Non-psychedelic psilocybin, derivatives and combinations: a platform of novel drug candidates for patients with metabolic and neuropsychiatric disorders
Our non-psychedelic psilocybin platform includes modified release (MR) psilocybin (REL-P11), PEG-psilocin and carbamate psilocin.
MR psilocybin
Modified release (MR) psilocybin (REL-P11) is a novel formulation with demonstrated lower Cmax and longer Tmax compared to IR psilocybin with compelling preclinical results for moving to Phase 2 proof of concept studies
Primary indication
Metabolic disorders (Colognesi 2025; AASLD 2024; Obesity Week 2024)
Murine model
High-fat high-fructose diet
Outcomes
Reduced hepatic steatosis, reduced triglycerides, reduced weight gain, improved glycemic control
Secondary indication
Recovery after occipital stroke with visual field loss (Society for Neuroscience 2024)
Murine model
Photothrombotic occipital stroke in Thy1-GFP mice
Outcomes
Improved visual task recovery and enhanced dendritic spine remodeling
Development stage
REL-P11 successfully completed a Phase 1 single ascending dose trial in overweight obese and in normal weight healthy volunteers. REL-P11 is Phase 2 ready
PEG-psilocin
PEG-psilocin (REL-P22) is a new chemical entity with low systemic exposure targeting GI and liver receptors
Primary indication
Metabolic disorders
Development stage
REL-P22 is undergoing preliminary IND-allowing preclinical studies
Carbamate-psilocin
Carbamate-psilocin (REL-P33) is a new chemical entity aimed at relieving neuropsychiatric disorders without psychedelic effects
Primary indication
Neuropsychiatric disorders
Development stage
REL-P33 is undergoing preliminary IND-allowing preclinical studies
Psilo+GLP1 agonist
Non-psychedelic MR psilocybin (REL-P11) and PEG-psilocin (REL-P22) combined with GLP1 agonists may offer synergistic therapeutic effects for the treatment of metabolic disorders with muscle preservation (Kargbo 2025)
Primary indication
Metabolic disorders
Development stage
REL-P44 is undergoing preliminary IND-allowing preclinical studies
Unleashing the therapeutic potential of non-psychedelic psilocybin derivatives
The psilocybin platform technology was co-invented in 2019 during a collaboration between scientists from the University of Padova and NeuroArbor.
RelmadaTherapeutics progressed the development of the psilocybin platform over the last 5 years. As of August 11, 2025, NeuroArbor licensed back its own technology. With a patient-centric mindset, the NeuroArbor team is fully focused on advancing the psilocybin platform through proof-of-concept Phase 2 studies.
A patient-centric platform
Patients and practicing physicians are eagerly awaiting novel safe and well tolerated medications for difficult to treat disorders such as NASH, metabolic disorders, neurological recovery and neuropsychiatric disorders.
The NeuroArbor team believes that the potential therapeutic effects of psilocybin and its derivatives can be successfully separated from psychedelic effects to create patient-friendly safe and effective drugs.